SCHEMBL5706368

SCHEMBL5706368

O=S(=O)(C(F)F)N(c1ccccn1)S(=O)(=O)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTPRC P08575 1/20 0.35
TSHR P16473 2/20 0.35
ATM Q13315 1/20 0.35
HSD17B10 Q99714 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
HTT P42858 1/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 1/20 0.35
MAPT P10636 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL254106 0.75 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2CYP2D6CYP2C19TSHR
SCHEMBL29443546 0.74 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2CYP2D6CYP2C19TSHR
SCHEMBL306348 0.74 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2CYP2D6CYP2C19TSHR
SCHEMBL5706356 0.71 HDAC6 (0.39) ALDH1A1SMN1; SMN2HSD17B10NPSR1KMT2A
SCHEMBL17397214 0.70 APOBEC3G (0.37) ALDH1A1SMN1; SMN2PTPRCTSHRHSD17B10
SCHEMBL17263229 0.67 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2CYP2D6CYP2C19TSHR
SCHEMBL29707064 0.67 KDM4E (0.46) PTPRCNPSR1KDM4ELMNA
SCHEMBL18322824 0.67 KDM4E (0.46) PTPRCNPSR1KDM4ELMNA
SCHEMBL31568294 0.66
SCHEMBL13338372 0.66 CYP2D6 (0.47) ALDH1A1SMN1; SMN2CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1696899-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2006-09-06 EP disclosed
WO-2005058301-A1 METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B ALLERGAN, INC. (US) 2005-06-30 WO disclosed